Search

Your search keyword '"Weiss, Michael S."' showing total 264 results

Search Constraints

Start Over You searched for: Author "Weiss, Michael S." Remove constraint Author: "Weiss, Michael S."
264 results on '"Weiss, Michael S."'

Search Results

1. The torus trick for configuration categories

2. Presentations of configuration categories

3. The configuration category of a covering space

5. The configuration category of a product

6. Integrated safety analysis of umbralisib, a dual PI3Kδ/CK1ε inhibitor, in relapsed/refractory lymphoid malignancies

7. Topological embeddings of disks via configuration categories

8. Ublituximab plus ibrutinib versus ibrutinib alone for patients with relapsed or refractory high-risk chronic lymphocytic leukaemia (GENUINE): a phase 3, multicentre, open-label, randomised trial

9. Dalian notes on rational Pontryagin classes

10. Truncated operads and simplicial spaces

11. Configuration categories and homotopy automorphisms

12. Occupants in manifolds

13. Spaces of smooth embeddings and configuration categories

14. Reply to Sayeed et al’s Reply to Reply

15. Automorphisms of Manifolds and Algebraic K-Theory: Part III

17. Tolerability and activity of ublituximab, umbralisib, and ibrutinib in patients with chronic lymphocytic leukaemia and non-Hodgkin lymphoma: a phase 1 dose escalation and expansion trial

18. Manifold calculus and homotopy sheaves

19. Functor calculus and the discriminant method

20. Rational Pontryagin classes and functor calculus

21. Smooth maps to the plane and Pontryagin classes, Part I: Local aspects

23. The stable moduli space of Riemann surfaces: Mumford's conjecture

24. Automorphisms of manifolds

27. Non-Invasive and Minimally Invasive Management of Low Back Disorders

29. Diagnostic Tests for Low Back Disorders

30. Phase 2 trial of umbralisib, ublituximab, and venetoclax in patients with relapsed/refractory mantle cell lymphoma.

32. Opioids and Safety-Sensitive Work

33. ACOEM Practice Guidelines : Opioids and Safety-Sensitive Work

34. Ublituximab versus Teriflunomide in Relapsing Multiple Sclerosis

35. Ublituximab (TG‐1101), a novel glycoengineered anti‐CD20 antibody, in combination with ibrutinib is safe and highly active in patients with relapsed and/or refractory chronic lymphocytic leukaemia: results of a phase 2 trial

37. Relapse Rate and Time to First Relapse Were Improved With Ublituximab vs Teriflunomide in the Phase 3 ULTIMATE I and ULTIMATE II Studies in Patients With Relapsing Multiple Sclerosis (RMS) (P1-1.Virtual)

38. Infusion-Related Reactions (IRRs) With Ublituximab in Patients With Relapsing Multiple Sclerosis (RMS): Post Hoc Analyses From the Phase 3 ULTIMATE I and II Studies (P6-4.010)

39. Ublituximab Treatment Is Associated With a Significant Proportion of Patients Achieving No Evidence of Disease Activity (NEDA): Results From the Ultimate I and Ultimate II Phase 3 Studies of Ublituximab vs Teriflunomide in Relapsing Multiple Sclerosis (RMS) (P6-4.005)

40. Disability Improvements With Ublituximab in Relapsing Multiple Sclerosis (RMS): Expanded Disability Status Scale (EDSS), 9-Hole Peg Test (9-HPT), and Timed 25-Foot Walk (T25FW) Evaluations From the Phase 3 ULTIMATE I and II Studies (P5-4.009)

42. Reply to Sayeed et al.

43. Favorable Outcomes for Patients Treated with U2 with Co-Morbidities or Concomitant Medications: A Retrospective Analysis of Unity-CLL Phase 3 Trial

44. Efficacy and Safety of Ublituximab in Combination with Umbralisib (U2) in Patients with Chronic Lymphocytic Leukemia (CLL) By Treatment Status: A Sub-Analysis of the Phase 3 Unity-CLL Study

45. IBCL-203: Umbralisib, a PI3Kδ/CK1ε Dual Inhibitor Demonstrates Marked Clinical Activity in Patients with Relapsed or Refractory Indolent Non-Hodgkin Lymphoma (iNHL): Results from the Phase 2 Global UNITY-NHL Trial

46. Poster: IBCL-203: Umbralisib, a PI3Kδ/CK1ε Dual Inhibitor Demonstrates Marked Clinical Activity in Patients with Relapsed or Refractory Indolent Non-Hodgkin Lymphoma (iNHL): Results from the Phase 2 Global UNITY-NHL Trial

47. Umbralisib Plus Ublituximab (U2) Is Superior to Obinutuzumab Plus Chlorambucil (O+Chl) in Patients with Treatment Naïve (TN) and Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL): Results from the Phase 3 Unity-CLL Study

48. Phase 2 study of the safety and efficacy of umbralisib in patients with CLL who are intolerant to BTK or PI3Kδ inhibitor therapy

49. Umbralisib, a Dual PI3Kδ/CK1ε Inhibitor in Patients With Relapsed or Refractory Indolent Lymphoma

50. Invasive Treatments for Low Back Disorders

Catalog

Books, media, physical & digital resources